Pular para o conteúdo
Merck
Todas as fotos(1)

Documentos Principais

Visualizar Toda a Documentação

L6668

Sigma-Aldrich

Lercanidipine hydrochloride

≥98% (HPLC), powder, dihydropyridine calcium-channel blocker

Sinônimo(s):

1,4-Dihydro-2,6-dimethyl-4-(3-nitrophenyl)-2-[(3,3-diphenylpropyl)methylamino]-1,1-dimethylethyl methyl ester 3,5-pyridinedicarboxylic acid hydrochloride

Faça loginpara ver os preços organizacionais e de contrato
Todas as fotos(1)

About This Item

Fórmula empírica (Notação de Hill):
C36H41N3O6 · HCl
Número CAS:
132866-11-6
Peso molecular:
648.19
Número MDL:
MFCD07773089
Código UNSPSC:
12352200
ID de substância PubChem:
24724527
NACRES:
NA.77

Nome do produto

Lercanidipine hydrochloride, ≥98% (HPLC)

Nível de qualidade

100

Ensaio

≥98% (HPLC)

Formulário

powder

condição de armazenamento

desiccated
protect from light

cor

yellow

originador

Forest Labs

temperatura de armazenamento

2-8°C

cadeia de caracteres SMILES

O=C(OC)C1=C(C)NC(C)=C(C(OC(C)(C)CN(C)CCC(C2=CC=CC=C2)C3=CC=CC=C3)=O)C1C4=CC([N+]([O-])=O)=CC=C4.Cl

InChI

1S/C36H41N3O6.ClH/c1-24-31(34(40)44-6)33(28-18-13-19-29(22-28)39(42)43)32(25(2)37-24)35(41)45-36(3,4)23-38(5)21-20-30(26-14-9-7-10-15-26)27-16-11-8-12-17-27;/h7-19,22,30,33,37H,20-21,23H2,1-6H3;1H

chave InChI

WMFYOYKPJLRMJI-UHFFFAOYSA-N

Ações bioquímicas/fisiológicas

Lercanidipine hydrochloride is a L-type (Cav1.2b) vascular channel antagonist; L-type (Cav1.2a) cardiac channel agonist voltage-dependent and highly lipophylic compound, which exhibits a slower onset and longer duration of action than other calcium channel antagonists; an antihypertensive agent in patients with mild-to-moderate hypertension; more vasoselective than lacidipine and amlodipine.
Lercanidipine hydrochloride is a L-type (Cav1.2b) vascular channel antagonist; L-type (Cav1.2a) cardiac channel agonist.

Características e benefícios

This compound was developed by Forest Labs. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Pictogramas

Skull and crossbones
GHS06

Palavra indicadora

Danger

Frases de perigo

H301

Declarações de precaução

P264 - P270 - P301 + P310 - P405 - P501

Classificações de perigo

Acute Tox. 3 Oral

Código de classe de armazenamento

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

Classe de risco de água (WGK)

WGK 3

Ponto de fulgor (°F)

Not applicable

Ponto de fulgor (°C)

Not applicable

Equipamento de proteção individual

Eyeshields, Faceshields, Gloves, type P2 (EN 143) respirator cartridges

Escolha uma das versões mais recentes:

Certificados de análise (COA)

Lot/Batch Number
114M4745V
017K47063
017K47062
017K47061
017K4706

Não está vendo a versão correta?

Se precisar de uma versão específica, você pode procurar um certificado específico pelo número do lote ou da remessa.

Pesquise por COA

Já possui este produto?

Encontre a documentação dos produtos que você adquiriu recentemente na biblioteca de documentos.

Visite a Biblioteca de Documentos

Os clientes também visualizaram

Slide 1 of 1

1 of 1

Ketoprofen ≥98% (TLC)

Sigma-Aldrich

K1751

Ketoprofen

Mehmet Gumustas et al.
Talanta, 82(4), 1528-1537 (2010-08-31)
In this study, pK(a) values were determined using the dependence of the retention factor on the pH of the mobile phase for three ionizable substances, namely, enalapril, lercanidipine and ramipril (IS). The effect of the mobile phase composition on the
Nitin Parmar et al.
Colloids and surfaces. B, Biointerfaces, 86(2), 327-338 (2011-05-10)
The present study deals with the development and characterization of self-nanoemulsifying drug delivery system (SNEDDS) to improve the oral bioavailability of poorly soluble third generation calcium channel blocker lercanidipine (LER). Solubility of the LER was estimated in various oils, cosurfactants
George Hadjipavlou et al.
Scandinavian journal of trauma, resuscitation and emergency medicine, 19(1), 8-8 (2011-01-22)
This case report describes the first reported overdose of the dihydropyridine calcium channel blocker (CCB) lercanidipine. A 49 yr old male presented to the Emergency Department 3 hrs after the ingestion of 560 mg of lercanidipine. In the department he
Arrigo F G Cicero et al.
Clinical and experimental hypertension (New York, N.Y. : 1993), 34(2), 113-117 (2011-10-05)
The aim of this study is to assess the blood pressure (BP) and metabolic effects of lercanidipine when combined with other classes of first-line antihypertensive drugs in day-to-day clinical practice. For this study, we consecutively enrolled 162 patients with uncomplicated
P-J Hsiao et al.
Clinical nephrology, 74(3), 217-222 (2010-09-24)
Lercanidipine, a novel dihydropyridine calcium channel antagonist, has been reported to cause sterile cloudy effluent in patients on continuous ambulatory peritoneal dialysis (CAPD). The purpose of the study was to evaluate the incidence and clinical course of cloudy effluent associated
Exibir todos os documentos relacionados

Artigos

Calcium Channels

We offers many products related to calcium channels for your research needs.

Nossa equipe de cientistas tem experiência em todas as áreas de pesquisa, incluindo Life Sciences, ciência de materiais, síntese química, cromatografia, química analítica e muitas outras.

Entre em contato com a assistência técnica